Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
Salvia Sanjay Jain
No relevant relationships to disclose
Yan G. Makeyev
No relevant relationships to disclose
Franco Muggia
No relevant relationships to disclose
James L. Speyer
No relevant relationships to disclose
John Patrick Curtin
No relevant relationships to disclose
Stephanie V. Blank
No relevant relationships to disclose
Leslie R. Boyd
No relevant relationships to disclose
Bhavana Pothuri
No relevant relationships to disclose
David Fishman
No relevant relationships to disclose
Xiaochun Li
No relevant relationships to disclose
Judith D. Goldberg
No relevant relationships to disclose
Amy Tiersten
No relevant relationships to disclose